David G. Maloney, MD, PhD, on Lymphomas: Treatment With CAR T Cells
2016 Pan Pacific Lymphoma Conference
David G. Maloney, MD, PhD, of Fred Hutchinson Cancer Research Center, discusses the efficacy of chimeric antigen receptor (CAR) T cells for lymphoma and their toxicity.
S. Vincent Rajkumar, MD, of the Mayo Clinic, and Sagar Lonial, MD, of the Emory University School of Medicine, discuss key issues in treating this disease, including monoclonal antibodies, plasmacytoma, and plasma cell leukemia.
Kieron M. Dunleavy, MD, of the National Cancer Institute, discusses the genomic landscape of aggressive lymphomas and how this is informing therapy decisions.
The ASCO
Beth M. Faiman, PhD, MSN, CNP, AOCN, of the Cleveland Clinic, discusses working with patients with multiple myeloma to minimize the toxicity of their treatment and improve their outcomes.
Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, reviews the data supporting current treatment approaches for T-cell lymphomas and discusses the specific subtype criteria used to individualize therapy.
Andrew D. Zelenetz, MD, of Memorial Sloan Kettering Cancer Center, discusses the pros and cons of these two regimens, with or without another agent, in diffuse large B-cell lymphoma.